Baylor

Pharmacogenomics informatics company OneOme will interpret and package data for Right 10K, a population-based PGx study in the US spearheaded by Mayo Clinic anf Baylor.

A Baylor College of Medicine-led team examined molecular alterations affecting the PI3K/AKT/mTOR pathway in 32 tumor types to identify functional changes.

For the first time, the researchers also found a clear difference in risk factors for high-grade glioblastoma versus low-grade glioma.

The funding will, in part, support efforts to expand the project's catalog of functional elements and understand their roles in different contexts.

The two new single-cell RNA-sequencing methods aim to overcome some of the limitations of single-cell transcriptomics.